Overview

DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

Status:
Not yet recruiting

Trial end date:
2025-04-01

Target enrollment:

Participant gender:

Summary

This study aims to find out whether treating children and young people living with HIV with two anti HIV medicines, dolutegravir and lamivudine, is safe and as effective as the three-medicine anti-HIV treatments currently used in routine practice.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

PENTA Foundation

Collaborators:

Advanced Pathogens Diagnostics Unit, University College London Hospitals
AMS-CMU/IRD (PHPT)
Baylor College of Medicine
Centre for Health Economics, University of York
Chiang Mai University
Chiangrai Prachanukroh Hospital
Chris Hani Baragwanath Academic Hospital
Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.
Department of Molecular and Clinical Pharmacology, University of Liverpool
Durban International Clinical Research Site
Great Ormond Street Hospital for Children NHS Foundation Trust
Hospital Universitario 12 de Octubre
Imperial College Healthcare Trust, St Mary's Hospital
Imperial College Healthcare Trust, St Mary’s Hospital
Joint Clinical Research Center
Kalasin Hospital, Kalasin
Khon Kaen Hospital
MRC CTU at UCL
MU-JHU CARE
Nakornping Hospital
Prapokklao Hospital, Chantaburi
University Hospital Birmingham NHS Foundation Trust

Treatments:

Dolutegravir
Lamivudine